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The translocator protein 18 kDa (TSPO) is overexpressed during 
neuroinflammation. TSPO- targeting tracers can be used to study 
neuroinflammation in diseases such as Alzheimer’s disease (AD) and stroke. 
[18F]F-DPA, a TSPO-specific tracer, is a recently developed analogue of 
[18F]DPA-714 and it was developed to improve the metabolic stability. The 
methylated version has been previously reported to have a high binding 
affinity. Hence, in this study the necessary precursor is synthesized and labeled 
with [11C]iodomethane. 
The purpose of this study is to synthesize a suitable precursor for labeling with 
[11C]CH3I and to introduce the [
11C]CH3 group onto the same position that is 
fluorinated [18F]F-DPA. 
 
 
 
The advantage of labeling with carbon-11 is to avoid using electrophilic and 
nucleophilic 18F-fluorination which have limitations during syntheses. Due to 
the F-DPA fast wash out, it would be suitable to label it with carbon-11.  
The pinacol boronic ester precursor was made successfully; although, 3-cyano-
N,N-diethyl-4- (iodophenyl)-4-oxobutanamide and pinacol boronic ester 
productions were time consuming and challenging especially the purification 
process.   
Keywords: [18F]F-DPA, TSPO, [11C]Me-DPA, [11C]CH3I 
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1. Introduction 
 
A radioactive tracer is a compound in which one atom has been replaced with a 
radioisotope. Tracking the radioactivity generated by this compound during decay 
enables the study of physiological and pharmacological mechanisms and operations in 
the human body.[1] 
Radioisotopes of hydrogen (H), carbon (C), nitrogen (N), oxygen (O), fluorine (F), 
phosphorus (P), sulfur (S), technetium (Tc), iodine (I), etc. can be used to track the 
distribution of a substance in biological systems such as cells and tissues by Positron 
Emission Tomography (PET), Single-Photon Emission Computed Tomography (SPECT, 
or SPET), and technetium scans. [1][2] 
The translocator protein (TSPO) with a molecular weight of 18 kDa [3], is an outer 
mitochondrial membrane protein [4]. TSPO-specific ligands are commonly used for brain 
imaging and this is due to the high expression of TSPO during neuroinflammation. TSPO 
is involved in cholesterol and porphyrin transport and plays a significant role in apoptosis 
[5][6].  
DPA-714 is a ligand of TSPO which has a high affinity of (Ki=7 nM) [7]. [
18F]DPA-714 
labeled with fluorine-18 has been used in PET imaging of brain tumors and 
neuroinflammation [8]. However is has been shown that this radiotracer is metabolically 
unstable and a more metabolically stable analogue, [18F]F-DPA, was developed [9].  
In F-DPA the fluorine atom is connected to the structure directly without a linker. The 
metabolism of [18F]DPA-714 lead to the cleavage of the radioactive label and the 
formation of non-specifically binding radioactive metabolites [10]. [18F]F-DPA was first 
synthesized by electrophilic fluorination [9] and nucleophilic syntheses have been 
developed by many research groups [11][12][13]. The evaluation in rats showed that the 
tracer had good entry into the brain and a fast washout, so that equilibrium was reached 
20-40 min after tracer injection [9]. Furthermore, comparison between brain samples of 
animals injected with [18F]F-DPA or [18F]DPA-714 showed that [18F]F-DPA had a higher 
metabolic stability compared to [18F]DPA-714. Moreover, it has also been used 
successfully to study neuroinflammation in a mouse model of AD [10]. 
The aim of this research is to synthesize a suitable precursor for labeling with [11C]CH3I 
and to introduce the [11C]CH3 group onto the same position that is fluorinated in [
18F]F-
DPA. 
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2. Literature review 
 
2.1. Nuclear Medicine  
Nuclear medicine is one of the most valuable diagnostics and therapeutic methods in 
medicine. Its emersion from the beginning has been a compilation of important historical 
discoveries. The field of nuclear medicine has grown tremendously over the past 20 years. 
One of the most useful and unique applications of nuclear technology is the production 
of radiopharmaceuticals, which are undoubtedly revolutionary in medical science. 
Radiopharmaceuticals which are used for diagnostic imaging purposes are called 
radiotracers [14][1]. 
From a structural point of view radiopharmaceuticals include a radionuclide and a carrier 
molecule with high binding power or affinity able to bind to biological molecules in order 
to target particular organs, cells or tissues during the treatments or studies of the body 
[14].  
The therapeutic uses of radiopharmaceuticals are more limited than the diagnostic 
applications. Radiation emitted by radiopharmaceuticals is widely used in cancer patients 
to kill cancer cells. The destruction of cancer cells is accomplished by ionization, so 
ionizing radiation with a short range is useful because this results in large amounts of 
tissue destruction in a small, confined area. The best isotopes for therapeutic purposes are 
those that emit low energy radiation like alpha or beta [15]. 
In radiopharmaceutical imaging, images of organs and tissues of interest can be presented 
by the scintigraphy process. It creates two-dimensional images and it functions based on 
radiotracer injection and distribution into tissues or bones which leads to formation of 
images. Consequently, images are obtained by a medical device known as gamma 
cameras that detects gamma rays [16]. On the other hand, SPECT and PET cameras 
produce three-dimensional images. Hence, they are classified as separate imaging 
techniques. Although, SPECT has lower detection sensitivity compared to PET [16]. 
PET and SPECT are often coupled with other imaging techniques such as Computed 
Tomography (CT) or Magnetic Resonance Imaging (MRI) which provide structural 
information [17][18]. 
CT scans were introduced to provide information about those elements which are more 
electron dense like bones. Whereas, MRI scans are applicable in sensitive organs which 
have more soft tissues. PET and SPECT scans have high sensitivity but relatively low 
resolution. They provide information about biological processes, these scans can be 
combined with CT or MRI to give more clear images, for example merging CT and PET 
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scans together (Figure 1) provides more vivid images with more details [17]. 
CT is a method for imaging by using radioactive x-rays many times and a variety of 
signals taken from different angles and processing them by computer which lead to a 3-
D image [19]. CT scan provides information to have better diagnosis of different diseases, 
injuries and traumas followed by better treatments. This method is fast and widely 
available for physicians to use it for both normal and emergency cases [19]. 
MRI combination with PET or SPECT provides perfect resolution for soft tissues (Figure 
1). This method has another advantage where the patient exposed to less radiation-dose 
[17]. 
 
 
Figure 1. Attenuation map (left), PET images (middle), and fused PET/CT images (right) of 
patient with multiple [18F]FDG–avid mediastinal and bihilar lymph node metastases.[20] 
 
In nuclear medicine technetium-99m is an extensively used radioisotope with 89% 
abundance (Table 1) for diagnostics of several diseases such as some types of cancers. 
For example, bone metastasis is detectable by technetium-99m-Methylene 
Diphosphonate (MDP). [15] 
 
Table 1. Physical Characteristics of Technetium-99m [21] *Abundance is the percent possibility 
of an emission type occurring with each decay 
Mode of decay Isomeric transition 
Physical half-life 6 hours 
Principal emissions (abundance)∗ Gamma rays 140 keV (89%) 
 
2.1.1 PET 
 
Positron Emission Tomography (PET) is a cross-sectional imaging method. In PET short 
lived positron emitting radionuclides are being used that accumulate in certain places. 
PET cameras produce three-dimensional images to scan the biomarkers or tracers in the 
brain or in the other organs. The principle of this method consists of a positron (β+) and 
an electron which have the same mass. Positron emitting radionuclides are produced by 
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cyclotrons via nuclear reactions. For example, production of fluorine-18 by oxygen-18 
bombardment through 18O(p,n)18F nuclear reaction [22][1]. The unstable proton-rich 
nucleus decays eventually to the stable form. A nuclear proton is converted to a neutron 
and is accompanied by the emission of a β+. Through the annihilation process, the β+ and 
an electron collide with each other and consequently two gamma photons of 511 keV are 
generated travelling in opposite directions [23][24]. The gamma photons can be detected 
and collected by a ring of scintillation detectors [24]. A tracer like [18F]FDG is injected 
to the body and it is consumed by the cancer cells which consume more glucose than 
normal cells. These tumor cells can be scanned by PET and they are shown brighter 
compare to the other tissues.[20] 
 
2.1.2 In vivo imaging  
 
PET radiopharmaceuticals are used in two ways of diagnosis: in vivo and ex vivo. 
In vivo techniques are those in which a radiopharmaceutical enters the body of a living 
patient. Gamma radiation is released from the β+ and electron annihilation passes through 
the body and is then received by radiation receivers and monitored to provide the desired 
information. This technique is highly sensitive, especially when coupled with CT or MRI. 
In vivo PET imaging is an invaluable diagnostic tool that is used around the world on a 
daily basis to diagnose patients, however it is also used in preclinical research studies. In 
preclinical PET laboratories healthy and diseased animals are studied to better understand 
diseases and to evaluate newly developed tracers [18][25]. 
 
2.1.3 Ex vivo imaging  
 
Ex vivo diagnostic methods are those performed on samples of organs taken from a test 
animal like mice and rats. In order to perform ex vivo imaging for example on the brain, 
the animal is killed and the brain is imaged to get desirable resolution images. In order to 
study the distribution of the radiolabeled tracer in tissues taken from lab animals, a special 
molecular imaging technique is used which is known as autoradiography. 
Autoradiography facilitates finding the amount of the accumulated radioactivity in the 
cells [26]. In order to increase the sensitivity and dynamic range, digital autoradiography 
is being used recently that provides better sensitivity and linearity [27]. 
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2.1.4 PET radionuclides and their production 
 
PET radionuclides are synthetic positron-emitting radioisotopes that are produced by 
either nuclear reactors or particle accelerators such as cyclotrons depending on the 
application purpose and the type of nuclide. In the process of radionuclide production, a 
stable atom is converted to an unstable atom. These nuclear reactions are accomplished 
by bombarding a target nuclide with high energy particles such as protons or alpha 
particles [28][29]. Accelerators are the sources for charged particles like fast electrons 
(β), heavy charged particles (α), neutrons and protons in the MeV range [28][29]. 
Generally, cyclotrons are more attractive for medical science compared to nuclear 
reactors. Products from cyclotrons are suitable for nuclear medicine imaging like SPECT 
and PET scans and other studies since the ratio of β+ particle and photon emission are 
high. Radionuclides produced by cyclotrons are generally have high Molar Activity (Am) 
since the nuclear reactions usually produce a different element from the target material. 
Carrier free refers to those radionuclides having high Am and the radioisotope of the 
element is in the pure form. In other word, the radionuclide has the abundance of 100% 
and the radioactive material does not contain the carrier. Examples of positron emitting 
radionuclides with short half-lives that are produced using a cyclotron are 11C 
(20.4 min), 13N (9.97 min), and 15O (2.03 min). Another important positron emitting 
radionuclide is Fluorine-18 with the half-life of 109.8 min which is widely used for 
labeling the glucose analog, 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) [1][21][30]. 
The nuclear reactor is a large source of thermal neutrons. These neutrons can easily be 
absorbed by stable isotopes, the resulting isotope will have an additional neutron which 
increases mass number by one unit. The resulting isotope may be radioactive, meaning 
there is a radioisotope, or it may be stable. The production is not carrier free and the Am 
is low. Examples of PET isotopes made this way are 32P, 90Y, 131I, 188Re and so on 
[31][28]. The maintenance of these reactors is challenging, and the maintenance costs are 
high [28][29]. 
 
18F-Fluoride can be produced via the 18O(p,n)18F nuclear reaction by the irradiation of 
18O-enriched water with a 10-MeV proton beam from a cyclotron. The labeling with 
fluorine-18 will be discussed in the radiolabeling section [32][22]. 
For the production of Carbon-11, the 14N(p,α)11C nuclear reaction is widely being used. 
Using a cyclotron, nitrogen gas is irradiated with a 10-MeV proton beam in the presence 
of O2 or H2 to generate [
11C]CO2 or [
11C]CH4 [33].  
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For carbon-11 labeling there two approaches known as Wet-chemistry approach and Gas- 
phase synthesis. Carbon-11 labeling will be discussed more in details later [34]. 
 
Table 2. Common positron emitting radionuclides [21] 
 
Isotope Half-life 
(T1/2) 
Max 
β+ 
Energy 
(MeV) 
β+ 
Emission 
(%) 
Target material and 
Natural abundance 
Nuclear 
reaction 
 
11C 20.4 min 0.96 99.8 14N (99.6%) 14N(p, α)11C 
13N 10.0 min 1.19 100 16O (99.76%) 16O(p,α)13N 
15O 2.07 min 1.73 100 15N (0.4%) 15N(p,n)15O 
18F 109.4 min 0.63 97.0 18O (0.2%) 18O(p,n)18F 
68Ga 68.2 min 1.89 89.3 Gen (68Ge), 
68Zn(18.5%) 
 
68Zn(p,n)68Ga 
66Zn(α,2n)68Ge 
64Cu 12.8 h 0.65 17.4 64Ni (0.9%) 64Ni(p,n)64Cu 
76Br 16.2 h 3.98 57.0 76Se (9.1%) 76Se(3He,xn)76Br 
89Zr 3.27 d 0.90 22.7 89Y (100%) 89Y(p,n)89Zr 
124I 4.18 d 2.13 25.0 124Te (4.8%) 124Te(d,2n)124I 
 
 
 
2.1.5 Radiolabeling 
 
Radiolabeling refers to a chemical reaction in which a radionuclide is introduced to the 
target molecule. In the manufacture of any labeled radiopharmaceutical, there should be 
a compromise between the chemical yield and the radioactive decay. Therefore, any 
radiopharmaceutical must be synthesized, purified and analyzed during the half-life of 
the radionuclide [32][1]. 
Radiochemical yield (RCY) refers to the amount of product activity relative to the starting 
radioactivity and is normally reported as a percentage. Later, the radiolabeled drugs can 
be utilized by injection to the patient’s body, inhalation or even orally [32]. 
As it was mentioned earlier, some practical radionuclides with short half-lives and high 
β+ decay ratio such as 11C, 15O, 13N, and 18F are used in PET radiopharmaceuticals. 
Radionuclides like fluorine-18 and carbon-11 have many significant advantages in 
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radiopharmaceutical field. Hence, there are different types of reactions for carbon-11 and 
fluorine-18 labeling [28]. 
In fluorine-18 radiolabeling there are two direct labeling methods for fluorination: 
Nucleophilic [18F]F- and Electrophilic [18F]F2 [32]. 
For 18F-radiolabeling, there are two cyclotron production methods which are carrier added 
to generate either [18F]F2 gas. The first method is via 
20Ne(d,α)18F nuclear reaction [35] 
and the second method is “2-shoot method” using the 18O(p,n)18F nuclear reaction on a 
18O2 gas target [36] with a subsequent isotope exchange reaction with fluorine gas which 
leads to low Am product. To reduce the carrier amount, the post-target production method 
for [18F]F2 was developed by Bergman and Solin [37] with high Am starting from aqueous 
[18F]F-. 
The low Am, low specificity and low yield are some of the disadvantages of electrophilic 
fluorination, although; there are still radiopharmaceuticals which are prepared using 
electrophilic fluorination such as [18F]fluoro-L-DOPA [32][38]. 
For nucleophilic fluorination, aqueous [18F]F- is produced with the same 18O(p,n)18F 
nuclear reaction explained in electrophilic fluorination. 18O-enriched water is irradiated 
with protons from a cyclotron. In nucleophilic fluorination Am is high and [
18F]FDG is 
produced via this method [32] (Scheme 1). 
 
 
Scheme 1.  [18F]-FDG molecule 
 
2.2. Carbon in chemistry 
 
Carbon is a non-metal light element and it can be found almost everywhere in nature. It 
is the element of life and the human body is made up of 20% of carbon by joining other 
elements like Oxygen and Hydrogen. Carbon can be found in a various allotropic forms 
including graphite, diamond, amorphous carbon and graphene which are the most known 
structures, additionally, in room temperature carbon remains in its solid state. Through 
different synthetic routes, carbon can be changed into multiple structures. These diverse 
structures have their own properties. 
8 
 
Carbon has fifteen known isotopes with atomic masses between 8C - 22C. The least stable 
of these isotopes is carbon-8 with a half-life of 2.0 x 10−21 seconds [21]. 
Naturally occurring carbon isotopes have three forms. Carbon-12 consists of 6 protons 
and 6 neutrons. Over 98 % of carbon on our planet is carbon-12 and the rest are other 
isotopic forms of carbon [21]. Carbon-13 is the heaviest stable isotope. Carbon-14 is a 
rare unstable isotope and has eight neutrons and it is the only radioactive isotope of carbon 
found in nature, and it will decay by beta emission overtime to nitrogen-14 [21]. 
Carbon-11 is the radioisotope of carbon consisting of 6 protons and 5 neutrons that decays 
99% by β+ emission and 0.2% by electron capture to boron-11 as shown in Table 3. It is 
one of the most used radioisotopes in PET [21]. 
 
Table 3. Nuclei and relative abundance of Carbon isotopes and masses in Dalton [21] 
 
Isotope Mass(Da) Natural 
Abundance 
(%) 
Half-life (T1/2) Decay mode 
11C 11.01143 - 20.36 min Electron 
capture,  
β+ 
12C 12.0 98.890 Stable - 
13C 13.003355 1.110 Stable - 
14C 14.003241 0.001 5730 Y β− 
 
2.2.1. Carbon-11 radionuclide and its chemistry 
 
In novel radiopharmaceutical development many factors are needed to be considered 
from radionuclide and labeling position selection to the precursor synthesis and labeling 
route [39]. 
Carbon-11 is one of the most useful radionuclides and one reason for this is that the 
introduction of carbon-11 into a biologically active molecule, does not affect the 
biochemical properties of the whole compound. Carbon-11 is commonly produced via 
the 14N(p,α)11C nuclear reaction. [11C]CO2 and [
11C]CH4 can be formed in the cyclotron 
target chamber, by adding oxygen and hydrogen to the target gas [39]. 
[11C]CO2 is the more functional of the two primary labeling precursors. [
11C]CO2 can 
react with primary amines, organolithium, organomagnesium compounds [40]. For 
example, preparation of [11C]acetone by the reaction of [11C]CO2 with methyl lithium 
[41].  
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Carbon chemistry provides much information to be used when developing carbon-11 
radiosynthetic methods. The short half-life of carbon-11 has both pros and cons at the 
same time. The short half-life of carbon-11 provides an opportunity to have in vivo studies 
and allows more injections on a patient or animal on the same day. On the other hand, the 
short half-life of carbon-11 makes some limitations for production and transportation of 
the 11C-labeled radiopharmaceuticals and short study frame [39]. 
Despite these limitations numerous radiolabeled molecules have been developed using 
the carbon-11 radionuclide [39]. 
 
2.2.2. CH3I 
 
In Carbon-11 chemistry, the most regular method for methylation is to use methylation 
agents like methyl iodide (MeI) and methyl triflate (MeOTf) which are derived from 
primary labeling precursor [11C]CO2. [
11C]MeI is the most frequently used secondary 11C-
labeling precursor but can be converted to the more reactive reagent [11C]MeOTf.. The 
11C-methylation reaction can be implemented based on the vial approach or solid support 
approach [39]. The regent in the gas phase can either be mixed with the small amount of 
precursor in solution or be passed through a capillary loop the internal surface of which 
is coated with the precursor solution. [11C]MeI can be used as an agent in the alkylation 
of carbanions and heteroatom nucleophiles which is the main application of this 
precursor, moreover, [11C]MeI has been used recently as an electrophile in palladium 
reactions to form 11C-C bonds which is a useful way for the labeling of substances with 
[11C]methyl groups onto specific positions [42][34]. 
[11C]MeI plays very important role for the formation of some other labeling precursors 
like L-and D-[methyl 11C]-L-methionine [43] and  [11C]nitromethane [44].  
[11C]CO is applicable in the synthesis of carbonyl compounds and this labeling precursor 
is as important as [11C]MeI for the syntheses of 11C-labeled radiotracers [42]. 
 
2.2.3. [11C]CH3I Synthetic methods 
 
There are two synthesis methods for [11C]MeI, these are the “wet-chemistry” approach 
and the alternative method is the “gas phase” method which will be explained 
subsequently [34]. 
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2.2.3.1. Wet-chemistry approach 
 
In the wet method, cyclotron generated [11C]CO2 is reacted with lithium aluminum 
hydride (LiAlH4) in dry THF or diethyl ether (Et2O) and the reason to use THF or Et2O 
is to trap and minimize the amount of incoming [11C]CO2. The solvent is then evaporated 
and a dry residue containing [11C]LiAl(OCH3)4 is formed. Water is required to be added 
to the residue to hydrolyze and release [11C]MeOH as an intermediate product, 
[11C]MeOH is added in the presence of nitrogen gas to the refluxing hydriodic acid (HI) 
and [11C]MeI will be formed [45] (Scheme 2). In another reaction, HI 57% (aq) is added 
to the dry complex of lithium, [11C]MeI is formed from hydrolyzed [11C]MeOH [46]. 
Alternatively, hydrolyzed [11C]MeOH is distilled and collected in a U-tube containing  
diphosphorous tetraiodide (P2I4) and then heated [47]. 
Triphenylphosphine diiodide (C6H5)3PI2 can also be used instead of P2I4 with the same 
reaction condition with [11C]MeI as an end-product [48]. 
After producing [11C]MeI by any of the mentioned reactions, it is transported with the 
current of an inert gas through a drying column to the methylation vessel for tracer 
radiosynthesis. RCY is reliable in the wet method but using LiAlH4 as a reducing agent 
has some disadvantages [42]. This reagent is a source of cold CO2 which causes 
contamination and results in low Am of [
11C]MeI, therefore, low Am of final 
11C-labeled 
radiotracer. To have a high Am of [
11C]MeI, the amount of LiAlH4 should be reduced 
[49]. To trap [11C]CO2 tiny amount of ~5-7 µmoles LiAlH4 would be enough to produce 
74 –370 GBq  at end of synthesis (E.O.S). 2M solution of LiAlH4 in distilled THF gives 
~2 µmoles of MeOH per ml [45]. The reduction of [11C]CO2 by LiAlH4 is not easy 
especially when Et2O is used as a solvent instead of THF in low temperature, EtOH is 
produced as a chemical impurity [49][34]. 
[11C]CO2 can be frozen in a small stainless steel loop, by submerging it in liquid Argon 
with the boiling point of -186 °C and then recovered from the trap by an inert gas (nitrogen 
or helium) flow as the loop is warmed to ambient temperature [50].  
There were some arguments earlier about the components that affect the presence of non-
radioactive elements and materials which cause low Am of radiotracers labeled with 
carbon-11. A hint of THF can remain in LiAlH4 after evaporation and this causes 
formation of MeOH and consequently CO2. The amount of CO2 thus formed can be 
reduced by decreasing the concentration of LiAlH4/THF solution [58]. LiAlH4 is the main 
source for carbon-12 contamination [52]. It is also believed that the contamination with 
non-radioactive carbon arises from the cyclotron process of [11C]CO2 production 
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[53][49]. Nowadays, it is clearly known that other factors can be sources of contamination 
such as quality of the reagents, target material, synthesis box, etc. and other system 
configuration of each site [42]. 
 
 
 
Scheme 2. Synthesis of [11C]MeI via 'wet' method [43]. 
 
2.2.3.2. Gas-phase synthesis 
 
Based on the difficulties and the low Am in the wet method, another procedure known as 
gas-phase method was developed. This approach starts with [11C]CH4. [
11C]CH4 can be 
produced in two ways. One is by 14N(p,α)11C  nuclear reaction in cyclotron using 5-10% 
H2/N2 target gas mixture in which Am is high [54] . The other way is to start with [
11C]CO2 
which is produced in cyclotron and then converted to [11C]CH4 by the hydrogen reduction 
process in the presence of Ni catalyst (Scheme 3) [34] in recirculation procedure. 
[55][56].  
 This involves the reaction of [11C]CH4 in H2 and Cl2 gas with CrO3 as a catalyst at 700 
°C which results in formation of [11C]CH3OH. Followed by conversion of [
11C]CH3OH 
to [11C]MeI by passing it over (C6H5)3PI2 adsorbed on alumina at 160°C. RCY is 
satisfactory in this method, but the Am is still low [57]. [
11C]MeI can also be formed from 
[11C]CH4 by a free radical iodination vapor reaction in the gas phase between 700-750 °C 
without using a catalyst [58][56]. The Am values are higher of those in wet method. 
Circulation process of gas-phase iodination is being performed to convert [11C]CH4 to 
[11C]MeI. By using the Porapak trap and heating, the formed [11C]MeI will be removed 
from the circulation process [59]. 
In another report [60] it is said that there are factors like I2 concentration, flow rate 
through the reactor tube, reactor temperature and if any changes happens on one 
parameter, the others must be reoptimized so, [11C]MeI yield will be maximized and 
[11C]CH2I2 would be minimized under recirculation system starting with [
11C]CO2 . With 
this method the RCY will be doubled. 
By combining [11C]CH4 with iodine vapors in a non-thermal plasma reactor under low-
pressure helium gas flow in a single-pass prototype device [11C]MeI vapor will be 
released. By this method different free radicals and other ions are produced within the 
plasma and the reaction product selectivity is low [61]. 
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Scheme 3. Synthesis of [11C]MeI via 'gas-phase' method [55][56] 
 
There are some advantages of using gas-phase method compare to classic wet method to 
prepare [11C]MeI. For instance, in the gas-phase method, since LiAlH4 and HI are not 
used, there is lower contamination with carbon-12 which results in higher Am and no need 
to do time consuming cleanings and dryings of the syntheses systems. When [11C]CH4 is 
produced in the target chamber, the highest radioactivity will be obtained [52]. 
Apart from the many benefits of using [11C]MeI, there are a few drawbacks of using this 
methylation agent. In the wet method, using HI causes the vials and tubes getting rusted 
overtime and the apparatus must be changed, cleaned and dried frequently. Some PET 
radiotracers indicate low RCY when [11C]MeI is used for heteroatom methylation 
reactions [42][62]. 
In these cases, more reactive [11C]MeOTf can be used [42][62]. The reaction of 
[11C]MeOTf is shown in scheme 4.  
 
 
Scheme 4. Synthesis of [11C]MeOTf from [11C]MeI [63] 
 
To put it in a nutshell, high Am compounds labeled carbon-11 are formed by the ‘gas 
phase’ method. So, this method is chosen when the receptors require a high Am tracer 
[42][34].  
 
2.2.4. Radiochemistry application of Carbon-11 
 
Radiotracers labeled with carbon-11 are applicable in early diagnosis of cancer [64], 
evaluation of the cancer treatment in therapeutic diagnostics [65], oncology imaging 
studies [66] and anticancer drug assessments [67]. Carbon-11 non-invasive PET studies 
are applicable to increase the therapeutic treatment results and identify those patients with 
metastatic disease [68]. 
There is a substitution process in which the nonradioactive element is replaced by its 
radioactive isotope in a biologically active tracer molecule without changing the 
biological properties. This process is called Hot-for-Cold substitution. In the case of 
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carbon element, carbon-11 is a substitute for carbon-12 in radiotracers labeled with 
carbon-11 [68]; some examples are [11C]acetate as a biomarker for fatty-acids [69], and 
[11C]choline as a marker for the synthesis of plasma membrane for the patients with 
neuroendocrine tumors [70]. Carbon-11 tracers are being used for imaging amino-acid 
transport for the patients with central nervous system (CNS) tumors [68]. 
Carbon-11 tracers are also applicable for imaging other diseases and organs. [11C]acetate 
PET imaging in renal [71] and pancreas [72] diseases. [11C]choline for prostate cancer 
diagnosis [73] [11C]methionine in lung cancer [74] and [11C]etomidate and 
[11C]metomidate for imaging of the adrenal cortex and its tumors [75] are only some of 
the examples of carbon-11 tracers in PET imaging. 
 
2.3. The Mitochondrial Translocator Protein (TSPO) 
 
TSPO 18 kDa, is a transmembrane protein [4] that shows the activation of monocytic 
lineage cells including microglia and macrophages during neuroinflammation [76]. TSPO 
is incorporated with other mitochondrial channels and regulates their activities like 
voltage-dependent anion channel (VDAC) and the inner membrane anion channel 
(IMAC) [5]. The TSPO monomer consists of five transmembrane domains while the 
whole molecule has dimeric quaternary structure and it can be found in steroidogenic 
tissues like brain, kidney and heart cells [77][78]. Other forms of TSPO molecule are 
monomeric and oligomeric [79]. TSPO works as a regulator of cholesterol transport [80] 
to the nucleus that is related to the cell proliferation [80] in the human body. 
TSPO was formerly called Peripheral Benzodiazepine Receptor (PBR) [4] due to the 1977 
discovery which showed the ability of this protein to bind benzodiazepine drugs outside 
of the CNS [81]. TSPO is highly available in steroid synthesizing cells [82][83]. 
Oncologic, endocrine, neuropsychiatric and neurodegenerative diseases are some of the 
clinical applications of TSPO modulation [5][7].  
Overexpressed TSPO acts as a target to detect neuroinflammation for PET ligands. TSPO 
PET imaging is a method for early diagnostics and theragnostic for CNS disorders [84]. 
 
2.3.1. Neuroinflammation  
 
Inflammation of the nervous tissue or neuroinflammation is a defensive immune response 
against many types of trauma or toxins. This response is biologically complicated and 
includes signaling proteins and receptors. Neuroinflammation comes from many 
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responses from resident glial cells in CNS [85]. Neuroinflammation regulation is carried 
out by neuronal, glial, and endothelial cells within the neurovascular unit activity. The 
neurovascular unit acts as a platform to integrate pro-inflammatory and anti-inflammatory 
mechanisms. Inflammatory mediators including cytokines, chemokines, reactive oxygen 
species can be produced in the brain either by resident cells or cells migrating from the 
peripheral blood [86]. This procedure causes deterioration in blood-brain barrier (BBB) 
that affects the progress of local inflammation [87][88]. 
Microglia are macrophages in CNS which are derived from the mesoderm. Microglia 
moderate the neuron and blood vessel functions. When the BBB is healthy and there are 
no blood-born cells present, microglia and perivascular cells are the primary immune 
defense for the brain. [89] 
In the condition that there is a neural injury or slight disorder in CNS environment, 
microglia react; coming up with faint physiological changes. This activation mode makes 
some changes in microglia morphology and leads them to the neuronal damage where 
release of proinflammatory molecules occurs. Microglia will be changed to the developed 
macrophages if the cells are dead. Due to this reason, they are called pathological sensor 
in the CNS [89]. 
Via two-photon microscopy, it is reported that resting microglia in healthy tissues 
frequently change their morphology due to processing, sampling and assessing the 
microenvironment. So, they are not passive all the time [90]. 
Microglial fast activation can happen without lymphocytic penetrations. This occurs in 
inflammatory brain disease known as multiple sclerosis (MS). The process elucidates 
neuroinflammation in different neurodegenerative disorders, such as AD, Parkinson’s 
disease (PD) and Huntington disease (HD) [91]. 
 
2.3.2. Alzheimer’s disease (AD) 
 
According to The National Institute on Aging (NIA) which is the lead agency for AD 
research at the National Institutes of Health (NIH) located in the U.S, AD is now 
considered as a major health problem and defined as an advancing irreversible brain 
disease in which memory is damaged and after a while becoming more serious and results 
in dementia. Dementia is classified in the neurodegenerative disorders, symptoms such 
as memory impairment and mental deterioration make it difficult for the person to do 
routine functions. The damage happens in hippocampus where the memories form [92]. 
It normally happens to the elderly people who are in their 60s and over and some 
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individuals with down syndrome who are in their 50s. In rare cases, it may occur in 
middle-age between the ages of 30 to 60. There are some common symptoms like memory 
loss and language problems which may show differently in various patients.  This disease 
is named after Dr. Alzheimer who found unusual changes in brain tissue of a patient 
which led to her death. He examined her brain and realized there are abnormal amyloid 
plaques and neurofibrillary tangles. The main reason for AD is amyloid plaques which 
can cause vascular dysfunction as well as affecting neuronal connectivity. Neurons are 
responsible for transferring messages from brain to organs and muscles. Consequently, 
when neuron cells die, other parts of the brain do not function appropriately. In the 
advanced level of this disease, brain tissue is considerably damaged and weakened 
[93][94]. 
Pathophysiology of AD starts some years before emersion of clinical symptoms, so it is 
possible to diagnose AD at early stages and essential to do so in order to control the 
progression. In this regard, [18F]F-FDG-PET/CT (Figure 2) is a promising tool to detect 
not only tumors but also neuroimaging application for AD diagnosis. Due to the glucose 
cerebral metabolism and neuronal activity indicator, PET can discern AD over other 
causes of dementia. PET tracers correspond to β-amyloid deposition in the brain also and 
the example of this would be the [11C]PiB [94][95] (Figure 2). 
 
Figure 2. [18F]FDG and [11C]PiB PET scans of a healthy brain (left side) and a patient with AD 
(right side). In both scans, standardized uptake value ratios to the cerebellum are indicated using 
a color-coded scale (range: 1–2.5) [96]. 
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2.3.3. PET tracers for TSPO and their applications in Neuroinflammation 
imaging 
 
TSPO radioligands facilitate detection of neuroinflammatory disorders by PET. Some of 
these ligands are [11C]PK11195, [11C]PBR28, [18F]DPA-714, [11C]DPA-713 and the 
newest [18F]F-DPA [97]. 
TSPO ligands can be used as diagnostic tools and many therapeutic applications to 
evaluate activation of microglia in human and animals [82]. 
[1- (2-chlorophenyl) -N - methyl -N- (1- methylpropyl)- 3- isoquinoline carboxamide] 
(PK11195) is a first-generation TSPO ligand (Scheme 5). It has been radiolabeled with 
carbon-11, and [11C](R)-PK11195 is used in PET to image brain diseases and detect 
neuroinflammatory changes in vivo [98]. The [11C](R)-PK11195 signal in vivo can be 
found in affected neural tracts and their cortical and subcortical areas. This ligand 
provides information about the progression of neuroinflammation and gives better 
understanding of brain disease and damage [92].  
[11C]PK11195 has poor signal-to-noise ratio [92] and high nonspecific binding, low brain 
uptake and high plasma protein uptake this results in not very accurate quantification [99]. 
Other second generation TSPO PET tracers have shown better results: for example 
[11C]PBR28 (Scheme 6) which has been used for pre-clinical and clinical imaging 
overexpressed TSPO for the detection and quantification of neuroinflammation in brain 
regions [100]. Although [11C]PBR28 is metabolized faster, it is more sensitive to detect 
neuroinflammation and TSPO overexpression in comparison with [11C]PK11195 tracer 
[101]. 
 
                                     
Scheme 5. [11C](R)-PK11195 structure                    Scheme 6. [11C]PBR28 structure                                        
 
2.3.4. Pyrazolopyrimidine-type TSPO Ligands 
 
In the following section second generation PET tracers for TSPO of the 
pyrazolopyrimidine-type are going to be discussed. 
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2.3.4.1. DPA-713 and DPA-714 
 
N,N-diethyl-2-[2-(4-[11C]methoxyphenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-
yl]acetamide ([11C]DPA-713) and N,N-diethyl-2-[2-(4-[18F]fluoroethoxyphenyl)-5,7-
dimethylpyrazolo[1,5-a]pyrimidin-3-yl]acetamide ([18F]DPA-714) are promising second 
generation TSPO-PET radiotracers [102][103] (scheme 7). 
In comparison between [11C]DPA-713 and  [11C]PK 11195 they have similar brain uptake 
but [11C]DPA-713 shows a better contrast of healthy and damaged brain, higher binding 
potential and higher signal-to-noise ratio since [11C]DPA-713  has lower lipophilicity. So, 
it can be concluded that [11C]DPA-713 is a suitable alternative to [11C]PK 11195 as a 
tracer for PET of TSPO expression. DPA-713 ligand has an excellent specificity and 
binding affinity of Ki = 4.7 ± 0.2 nM. [102]. 
[18F]DPA-714 also has a high binding affinity of Ki = 7nM and low non-specific binding. 
A comparison between [11C]PK11195 and [18F]DPA-714 [104] shows that both TSPO 
tracers have similar brain uptake. Brain uptake value refers to the ability of drug transport 
across the BBB. In the case of [11C]PK11195 and [18F]DPA-714 brain uptake values are 
3.3±1.2 %ID/g and 4.6±2.5 %ID/g respectively and [18F]DPA-714 shows a significantly 
better signal-to-noise ratio. The advantage of using this tracer is due to its longer half-life 
of F-18 which enables the tracer to be distributed widely in the brain and its increased 
bioavailability in brain tissue makes [18F]DPA-714 a suitable replacement for 
[11C]PK11195. Furthermore, F-18 has low β+ range and better image quality [104]. 
[11C]-DPA-713 is more suitable for imaging mild inflammation. In addition, the fact that 
[18F]-DPA-714 is an agonist PET tracer providing evaluation of different aspects of 
neuroinflammation [105]. 
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Scheme 7. Synthesis of [11C]DPA-713 and [18F]DPA-714 from the labeling precursor compounds 
1 and 3 respectively [105]. 
 
2.3.4.2. F-DPA 
 
TSPO ligands are developing considerably and new studies and results are constantly 
being published which indicates high potential for research in the area of TSPO 
radiotracers. In 2001 Selleri et al. [106] were looking into many different 
pyrazolopyrimidineacetamide ligands. They described a new TSPO ligand N,N-Diethyl-2-(2-
(4-fluorophenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)acetamide which had a 
high binding affinity of Ki = 9.2 ± 1.0 nM for TSPO. 
In the recent years, new reports were published by Damont et al. [107] in 2015. They 
carried out a nucleophilic synthesis of [18F]F-DPA by employing different precursors but 
the Am was relatively poor.  
Due to the difficulties in the nucleophilic labeling Keller et al. [9] employed electrophilic 
18F-fluorination for the synthesis of [18F]F-DPA (Scheme 8). It was shown that [18F]F-
DPA is metabolically more stable than [18F]DPA-714 and that [18F]F-DPA has a quick 
entry into the brain [9]. [18F]F-DPA has also successfully  been applied to study 
neuroinflammation in a mouse model of AD [11]. 
Other research groups Wang et al. [12] and Zischler et al. [13] have developed 
nucleophilic 18F-fluorination syntheses for [18F]F-DPA with moderate Am’s. Wang et al. 
used a spirocyclic iodonium ylide as precursor and evaluated brain uptake of this tracer 
in a mouse model with AD and a rat model with ischemic stroke. Zischler et al. used a 
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boronic ester precursor and a novel method to prepare radiofluorinated [18F]F-DPA 
(Scheme 9). 
A considerable difference between [18F]DPA-714 and [18F]F-DPA is that there is no 
alkoxy linker to connect label and the aromatic ring [10].  
 
 
Scheme 8. Electrophilic synthesis of [18F]F-DPA [9] 
 
Scheme 9. Synthetic route of [18F]F-DPA [13] 
 
2.3.4.3. Me-DPA 
 
In their article from 2001, Selleri et al. also described N,N-Diethyl-2-(2-(4-
methylphenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)acetamide (Me-DPA). This 
structure is an attractive potential tracer due to the binding affinity (Ki = 0.8 ± 0.1 nM) 
which is ten times more than that of F-DPA, (Ki = 9.2 ± 1.0 nM) [106]. Moreover, there 
is no restriction of carbon-11 labeling compared to nucleophilic and electrophilic 
fluorinations that makes the labeling process easier.  
In this work, it is planned to make a boronic ester precursor which can be labeled with 
[11C]-Me as shown in the scheme 10.  
 
Scheme 10. Conversion of the boronic ester to [11C]Me-DPA 
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3.Results 
 
3-(4-Iodophenyl)-3-oxopropanenitrile 
To produce pinacol boronic ester a synthesis with five steps was carried out. In the first 
step, 3-(4-Iodophenyl)-3-oxopropanenitrile was produced in 70% yield from methyl 4-
iodobenzoate as starting material.  As it can be observed from the 1H NMR (CDCl3, 500 
MHz) 3-(4-Iodophenyl)-3-oxopropanenitrile, the aromatic protons are at 7.9 ppm (d, 2H, 
Ph) and 7.8 ppm (d, 2H, Ph) and methylene protons are at 3.9 ppm (s, 2H, CH2CN). A 
tiny amount of THF might be present in the product.  
 
 
 
Figure 6. 1H NMR (CDCl3, 500 MHz) 3-(4-Iodophenyl)-3-oxopropanenitrile 
 
3-Cyano-N,N-diethyl-4-(4-iodophenyl)-4-oxobutanamide 
In the second synthesis step, 3-Cyano-N,N-diethyl-4-(4-iodophenyl)-4-oxobutanamide 
was produced from the 3-(4-Iodophenyl)-3-oxopropanenitrile in 70% yield. As it can be 
observed from the 1H NMR (CDCl3, 500 MHz) 3-Cyano-N,N-diethyl-4-(4-iodophenyl)-
4-oxobutanamide, the aromatic protons are at 7.9 ppm (d, 2H, Ph) and 7.7 ppm (d, 2H, 
Ph), a methine proton is at 4.9 ppm (dd, 1H, CHCN), the methylene protons are at 3.4 – 
3.3ppm (m, 5H, NCH2, COCH2) and 2.89 ppm (dd, 1H, COCH2), the methyl protons are 
at 1.27 ppm (t, 3H, CH3) and 1.1 ppm(t, 3H, CH3). The product is pure enough to continue 
to the next synthesis.   
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Figure 7. 1H NMR (CDCl3, 500 MHz) 3-Cyano-N,N-diethyl-4-(4-iodophenyl)-4-
oxobutanamide 
 
2-(3-Amino-5-(4-iodophenyl)-1H-pyrazol-4-yl)-N,N- diethylacetamide) 
In the third synthesis step, 2-(3-Amino-5-(4-iodophenyl)-1H-pyrazol-4-yl)-N,N- 
diethylacetamide) is produced from the starting material 3-Cyano-N,N-diethyl-4-(4-
iodophenyl)-4-oxobutanamide in 52% yield. As 1H NMR (CDCl3, 500 Mhz) 2-(3- 
Amino-5-(4-iodophenyl)-1H-pyrazol-4-yl)-N,N- diethylacetamide) indicates the 
aromatic benzene protons are at 7.7 ppm (d, 2H, Ph) and 7.1 ppm (d, 2H, Ph), the 
methylene protons are at 3.5 ppm (s, 2H, COCH2), 3.3 ppm (q, 2H, COCH2) and 3.1 ppm 
(q, 2H,  NCH2), the methyl protons are at 1.1 ppm  (t, 3H, CH3) and at 1 ppm (t, 3H,  
CH3). The NMR shows pure product. 
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Figure 8. 1H NMR (CDCl3, 500 MHz) 2-(3-Amino-5-(4-iodophenyl)-1H-pyrazol-4-yl)-
N,N- diethylacetamide) 
 
N,N-Diethyl-2-(2-(4-iodophenyl)-5,7-dimethylpyrazolo[1,5-a]-
pyrimidin-3-yl)acetamide 
In the fourth synthesis step, N,N-Diethyl-2-(2-(4-iodophenyl)-5,7dimethylpyrazolo[1,5-
a]-pyrimidin-3-yl) acetamide is produced in 95% yield from the 2-(3-Amino-5-(4-
iodophenyl) -1H-pyrazol-4-yl)-N,N- diethylacetamide)  as the starting material. As it can 
be induced from 1H NMR (CDCl3, 500 MHz) N,N-Diethyl-2-(2-(4-iodophenyl)-5,7-
dimethylpyrazolo[1,5-a]-pyrimidin-3-yl)acetamide, the aromatic benzene protons are at 
7.7 ppm  (d, 2H, Ph) and 7.6 ppm (d, 2H, Ph),  4-pyrimidine proton is at 6.5 ppm (s, 1H, 
CHCN),  the methylene protons are at 3.9 ppm (s, 2H, COCH2), 3.5 ppm (q, 2H, NCH2) 
and 3.4 ppm (q, 2H, NCH2), the methyl protons are at 2.7 ppm (s, 3H, PhCH3), 2.5 ppm  
(s, 3H, PhCH3), 1.2 ppm (t, 3H, CH3) and 1.1 ppm (t, 3H, CH3). The product has high 
purity. 
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Figure 9. 1H NMR (CDCl3, 500 Mhz) N,N-Diethyl-2-(2-(4-iodophenyl)-5,7-
dimethylpyrazolo[1,5-a]-pyrimidin-3-yl)acetamide 
 
2-(5,7-dimethyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) 
phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)-N,N-diethylacetamide 
In the fifth synthesis step which leads to the pinacol boronic ester in 19% yield, N,N-
Diethyl-2-(2-(4-iodophenyl)-5,7-dimethylpyrazolo[1,5-a]-pyrimidin-3-yl)acetamide is 
used as the starting material. Based on the NMR measurement from 1H NMR (CDCl3, 
500 MHz) pinacol boronic ester, the aromatic benzene protons are at 7.89 ppm  (d, 2H, 
Ph) and 7.83 ppm (d, 2H, Ph),  4-pyrimidine proton is at 6.5 ppm (s, 1H, CHCN),  the 
methylene protons are at 3.95 ppm (s, 2H, COCH2), 3.5 ppm (q, 2H, NCH2) and 3.4 ppm 
(q, 2H, NCH2), the methyl protons are at 2.7 ppm (s, 3H, PhCH3), 2.5 ppm  (s, 3H, 
PhCH3), 1.3 ppm (s, 12H, CH3 ), 1.2 ppm (t, 3H, CH3) and at 1.1 ppm (t, 3H, CH3).  
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Figure 10. 1H NMR (CDCl3, 500 MHz) pinacol boronic ester  
 
4. Discussion  
 
The aim of the presented work was to make a suitable precursor which can be labeled 
with carbon-11. There are factors affects the precursor selection such as stability, binding 
affinity, PH, thermal resistance and so on. 
For this work, the boronic ester was chosen to synthesize as the precursor due to some 
reasons. First, boronic ester is a non-toxic compound compared to many other toxic 
organometallic precursors. Another advantage of this precursor is the stability of it for a 
long-term storage in comparison with the boronic acid. Boronic esters can be coupled 
with electrophiles, they can be used for reactions with nucleophiles; for example, the 
copper mediated fluorination, this makes them useful and versatile reagents. In this work 
130 mg of the precursor was made. Although, the yield of the final reaction was low, and 
the final purification was challenging, enough precursor was prepared to perform the 
radiolabeling. The precursor will be used in radiolabeling with [11C]CH3I.  
The purification challenges were due to the starting material and the product same 
retention time which caused using different eluents with variety of percentages.  
Phenylboronic pinacol ester precursor was produced by Pd- catalyzed coupling reaction 
of  B2Pin2 and adding N, N-Diethyl-2-(2-(4-iodophenyl)-5,7-dimethylpyrazolo[1,5-a]-
pyrimidin-3 yl)acetamide in the presence of potassium acetate. 
 
The boronic ester precursor can be used to synthesize both Carbon-11 and Fluorine-18 
labeled PET tracers via [11C]methylation, [18F]fluoromethylation and nucleophilic and 
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electrophilic [18F]fluorination. 
Since boronic ester has higher lipophilicity compared to other boronic acid and lipophilic 
esters, the retention time is increasing and that results in better separation during tracer 
purification by HPLC. 
In the future, the radiochemistry reaction and  HPLC methods for analysis and 
purification will be developed. 
 
5. Materials and methods 
 
5.1. Precursor production 
 
3-(4-Iodophenyl)-3-oxopropanenitrile 
For the preparation of pinacol boronic ester the following method [107] was used.  
In the first step 3-(4-Iodophenyl)-3-oxopropanenitrile was made. For this synthesis, a 
round bottom flask with a magnetic stirrer was placed in the cooling bath adding 50 mL 
of anhydrous THF to the flask by glass syringe while covering the flask by a septum in 
order to prevent any moisture or water entering to the flask and the synthesis must be 
carried out in dry condition. Then cooling bath was made by adding liquid nitrogen to 
MeOH. The temperature was kept at around -60 °C. 40 mL (100 mmol) n-butyllithium 
solution (2.5 M) in hexane was added the same way by glass syringe. Then 5.2 mL (100 
mmol) CH3CN in 50 mL of anhydrous THF was added to the flask slowly over 15-20 min 
while the temperature was below -50 °C. The mixture was stirred for 30 min at -60 °C. 
In another vial 12 g (45.8 mmol) methyl 4-iodobenzoate was dissolved in 70 ml of 
anhydrous THF and then added to the flask mixture over 20 min at -60 °C and after the 
addition, the reaction mixture was kept at the same temperature while stirring for 1 h. For 
the next 2 h the temperature was kept around -45 °C. After the mixing was completed. 
TLC monitoring was done to check if the reaction was completed. In order to quench the 
reaction, 200 ml of milli-Q water was added to the flask under vigorous stirring and the 
mixture was transferred to a beaker. Concentrated hydrochloric acid was added to the 
mixture to acidify the aqueous layer to pH 2. A white inorganic precipitate was formed 
and filtered by a funnel. The filtrate was extracted twice with EtOAc and washed twice 
with milli-Q water twice and once with brine. The organic phase was dried over sodium 
sulfate and filtered. Then organic phase was evaporated to dryness and the product was 
recrystallized from EtOAC as a purplish beige solid. 
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3-Cyano-N,N-diethyl-4-(4-iodophenyl)-4-oxobutanamide 
 
In a flask with stirrer 0.285 g (7.085 mmol) of sodium hydroxide was added and dissolved 
in 35 mL EtOH and 6 mL of milli-q water. 1.757 g (6.5 mmol) of 3-(4-Iodophenyl)-3-
oxopropanenitrile was added to the flask and stirred for 30 min at room temperature. 1.95 
g (13 mmol) of sodium iodide was added to the mixture in one portion and dropwise 
addition of 0.99 mL (6 mmol) of N,N-diethylchloroacetamide to it. The reaction was 
stirred for 4 days at room temperature and monitored by TLC (Toluene / EtOAc 20%). 
The organic salt formed was removed by filtration under suction. The filtrate was 
evaporated to dryness. The purification was done by column chromatography with 
toluene/EtOAc 20% as an eluent. The starting material came out first and then the product 
with brownish beige color.  
 
 
2-(3-Amino-5-(4-iodophenyl)-1H-pyrazol-4-yl)-N,N- diethylacetamide) 
 
In the third step 2-(3-Amino-5-(4-iodophenyl)-1H-pyrazol-4-yl)-N,N- diethylacetamide) 
was made. To the 1.6g (4.2 mmol) of 3-Cyano-N,N-diethyl-4-(4-iodophenyl)-4-
oxobutanamide in a flask was added 24 mL of EtOH followed by addition of 630 μL (12.9 
mmol) of monohydrated hydrazine and 460 μL (7.7 mmol) of glacial acetic acid and it 
was placed in a bath oil with stirrer and a thermometer. The mixture was heated at reflux 
for 8 h while monitoring the progress by TLC. Then evaporated to dryness. The residue 
was extracted with EtOAC and water and basified by 3 M sodium hydroxide aqueous 
solution at pH 10. The organic layer was washed with water twice and brine, the organic 
layer was dried with sodium sulfate. Then it was filtered and concentrated to dryness by 
vacuum evaporator. The cold diethyl ether was added to the residue to collect solid 
particles, subsequently washed twice with cold diethyl ether followed by vacuum-drying. 
Eventually, the pure product was collected. 
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N,N-Diethyl-2-(2-(4-iodophenyl)-5,7-dimethylpyrazolo[1,5-a]-
pyrimidin-3-yl)acetamide 
 
In the fourth step, N,N-Diethyl-2-(2-(4-iodophenyl)-5,7-dimethylpyrazolo[1,5-a]-
pyrimidin-3-yl)acetamide was made by adding 0.875 g (2.2 mmol) of 2-(3-Amino-5-(4-
iodophenyl)-1H-pyrazol-4-yl)-N,N-diethylacetamide) in  17.5 mL of EtOH  and 363 μL 
(28.2 mmol) of acetylacetone in a flask and placing that in an oil bath with a stirrer and 
thermometer. The reaction was stirred under reflux for 6 h and then cooled down to room 
temperature overnight. The pure product crystallized in the flask. The remaining organic 
phase was concentrated, and more product was collected by crystallization. 
 
 
5.1.2. production of pinacol boronic ester 
 
For the last step the pinacol boronic ester synthesis was done. 0.2 g (0.43 mmol) of N,N-
Diethyl-2-(2-(4-iodophenyl)-5,7-dimethylpyrazolo[1,5-a]-pyrimidin-3-yl)acetamide, 35 
mg (10 mol %) of [1,1′Bis(diphenylphosphino)ferrocene]dichloropalladium(II), 0.127 g 
(1.3 mmol) of Potassium acetate and 0.218 g (0.86 mmol) of bis(pinacolato)diboron 
(B2Pin2) were added to a small flask and covered by a septum to prevent any moisture to 
enter and 5 mL of dry toluene was added by syringe to it under the argon flow. The flask 
was purged with argon and placed in an oil bath with the stirrer and the thermometer. The 
mixture was heated up to reflux around 100 °C for 48 h. TLC monitoring was done.  
The reaction mixture extracted with EtOAC, water and brine. The organic layers were 
dried with sodium sulfate, filtered, and evaporated to dryness. The product was purified 
by column chromatography with CH3CN as eluent. 
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5.2. Characterization methods 
 
5.2.1. Nuclear Magnetic Resonance (NMR) spectroscopy 
 
The NMR instrument used in this project is Bruker 500 MHz (TYBruker500) for all the 
measurements. The temperature of instrument is set to 98 K. Approximately 750 µl of 
deuterated solvent was used for the NMR tube corresponding to 6 cm level of solvent. 
 
5.2.2. Thin layer chromatography (TLC) 
 
TLC chromatography was used to analyze the mixtures by separating the compounds. 
In this work, several TLC measurements during and after each synthesis and reactions. 
 
5.2.3. Column chromatography 
 
It is used for purification of compounds and consists of a column, silica gel and eluent 
which is called mobile phase. In this work, several purifications carried out on the second 
and fifth steps using different eluents and percentages.  
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7. Abbreviation list 
 
AD   Alzheimer’s Disease  
Am   Molar activity 
β+   Positron 
B2Pin2   Bis(pinacolato)diboron 
BBB   Blood-brain barrier 
CT   Computed Tomography 
CH2I2   Diiodomathane  
CH3CN   Acetonitrile  
(C6H5)3PI2  Triphenylphosphine diiodide   
CNS   Central Nervous System 
DPA-714 N,N-diethyl-2-[4-(2-fluoroethoxy)phenyl]-5,7-
dimethylpyrazolo[1,5-a]pyrimidine-3-acetamide  
DPA-713 N,N-diethyl-2-(4-methoxyphenyl)-5,7-dimethylpyrazolo[1,5-
a]pyrimidine-3-acetamide 
EtOAc   Ethyl acetate 
EtOH   Ethanol 
F-DPA N,N-Diethyl-2-[4-fluorophenyl]-5,7-dimethylpyrazolo[1,5-
a]pyrimidine-3acetamide 
[18F]FDG  2-[18F]Fluoro-2-deoxy-2- D-glucose     
[18F]F-   [18F]Fluoride ion 
HI   Hydroiodic acid 
MeI   Methyl Iodide  
MeOTf   Methyl triflate  
MeOH   Methanol 
MRI   Magnetic Resonance Imaging 
NMR   Nuclear Magnetic Resonance 
PBR   Peripheral benzodiazepine receptor 
PK111195 [1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-
isoquinoline carboxamide] 
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PET   Positron Emission Tomography 
P2I4   Diphosphorous tetraiodide 
RCY   Radiochemical yield 
SPECT   Single - Photon Emission Computed Tomography 
TSPO   18kDa Translocator Protein  
TLC   Thin Layer Chromatography 
THF   Tetrahydrofuran  
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